/PRNewswire/ Soterix Medical Inc. announces the launch of a Phase-2 clinical trial that will evaluate the combination of REMOTE-tDCS and a brain training.
Share this article
Share this article
NEW YORK, Jan. 26, 2021 /PRNewswire/ Soterix Medical Inc. (SMI), the global leader in non-invasive stimulation and synergistic brain imaging technologies, announces a new clinical trial of home-based auricular Vagus Nerve Stimulation (taVNS) for individuals who experience post-COVID neuropsychiatric symptoms, like fatigue, headache, or anxiety. The trial involves an innovative, first-of-its kind home-based neuromodulation solution that combines Soterix Medical s unique wearable taVNS platform, with ElectraRx™ portal for remote stimulation control, and home-based vital sign monitoring.
Emerging studies show COVID can affect patients during two distinct phases of the disease process: the acute stage, characterized by fever, heart or lung problems, and the post-COVID phase, in which neuropsychiatric symptoms, like fatigue, anxiety and depression, can occur.